Horizon Therapeutics confirms FTC Second Request in Amgen deal
JHVEPhoto


Horizon Therapeutics (NASDAQ:HZNP) and Amgen (NASDAQ:AMGN) confirmed the companies received a "Second Request" from the Federal Trade Commission in regards to the planned almost $28 billion acquisition of the rare-disease focused company. Horizon fell 0.8% in after hours trading.
Horizon (HZNP) and Amgen (AMGN) each received a request for additional information and documents from the FTC on Monday, according to an 8-K filing .Both parties intend to promptly respond to the second request and to continue to work cooperatively with the FTC in its review.

CTFN earlier Tuesday reported on the second request news.

Amgen (AMGN) agreed to Horizon Therapeutics for $116.50 per share in cash last month, valuing the Ireland-based biotech at nearly $27.8 billion.

The FTC request comes as Sen. Elizabeth Warren (D-MA) on Wednesday wrote a letter to the the antitrust regulator about her concerns with the transaction. 

Amgen on Tuesday after the close reported Q4 non-GAAP EPS of $4.09 in-line, revenue of $6.8B beat by $30 million.